格菲妥单抗治疗复发/难治性套细胞淋巴瘤:I/II期研究结果
NP30179 I/II期研究评估格菲妥单抗单药(奥妥珠单抗预处理)治疗复发/难治套细胞淋巴瘤,60例可评估患者完全缓解率78.3%、总缓解率85.0%,细胞因子释放综合征发生率70.0%,安全性可控。
要点
- 固定疗程格菲妥单抗在重度经治复发/难治套细胞淋巴瘤中完全缓解率达78.3%。
- 既往接受BTK抑制剂者完全缓解率71.0%、总缓解率74.2%。
- 细胞因子释放综合征发生率70.0%,2000 mg预处理组低于1000 mg组。
核心结论
- 固定疗程格菲妥单抗在重度经治复发/难治套细胞淋巴瘤患者中诱导高完全缓解率,安全性谱在适当支持治疗下可控。
研究设计与样本
- I/II期NP30179研究(ClinicalTrials.gov标识符NCT03075696)评估格菲妥单抗单药治疗复发/难治B细胞淋巴瘤,采用奥妥珠单抗预处理以降低细胞因子释放综合征风险。
- 纳入至少接受过一种既往治疗的复发/难治套细胞淋巴瘤患者,共入组61例,60例可评估安全性和疗效。
- 奥妥珠单抗预处理(1000或2000 mg)于首次格菲妥单抗给药前7天给予,格菲妥单抗第1周期第8天2.5 mg、第15天10 mg阶梯递增给药,第2周期第1天起目标剂量16或30 mg每3周一次,共12周期。
主要发现
- 患者既往治疗中位数为2线(范围1-5)。
- 完全缓解率为78.3%(95%CI 65.8-87.9),总缓解率为85.0%(95%CI 73.4-92.9)。
- 既往接受BTK抑制剂治疗者(n=31)完全缓解率71.0%(95%CI 52.0-85.8),总缓解率74.2%(95%CI 55.4-88.1)。
- 格菲妥单抗给药后细胞因子释放综合征发生率为70.0%,2000 mg奥妥珠单抗预处理组发生率63.6%(≥2级22.7%),低于1000 mg组的87.5%(≥2级62.5%)。
- 4例不良事件导致格菲妥单抗停药,均为感染。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) have a poor prognosis. The phase I/II NP30179 study (ClinicalTrials.gov identifier: NCT03075696) evaluated glofitamab monotherapy in patients with R/R B-cell lymphomas, with obinutuzumab pretreatment (Gpt) to mitigate the risk of cytokine release syndrome (CRS) with glofitamab. We present data for patients with R/R MCL. METHODS: Eligible patients with R/R MCL (at least one previous therapy) received Gpt (1,000 or 2,000 mg) 7 days before the first glofitamab dose (single dose or split over 2 days if required). Glofitamab step-up dosing was administered once a day on days 8 (2.5 mg) and 15 (10 mg) of cycle 1, with a target dose of 16 or 30 mg once every 3 weeks from cycle 2 day 1 onward, for 12 cycles. Efficacy end points included investigator-assessed complete response (CR) rate, overall response rate (ORR), and duration of CR. RESULTS: Of 61 enrolled patients, 60 were evaluable for safety and efficacy. Patients had received a median of two previous therapies (range, 1-5). CR rate and ORR were 78.3% (95% CI, 65.8 to 87.9) and 85.0% (95% CI, 73.4 to 92.9), respectively. In patients who had received previous treatment with a Bruton tyrosine kinase inhibitor (n = 31), CR rate was 71.0% (95% CI, 52.0 to 85.8) and ORR was 74.2% (95% CI, 55.4 to 88.1). CRS after glofitamab administration occurred in 70.0% of patients, with a lower incidence in the 2,000 mg (63.6% [grade ≥2, 22.7%]) versus 1,000 mg (87.5%; grade ≥2, 62.5%) Gpt cohort. Four adverse events led to glofitamab withdrawal (all infections). CONCLUSION: Fixed-duration glofitamab induced high CR rates in heavily pretreated patients with R/R MCL; the safety profile was manageable with appropriate support.
引用
- Phillips TJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. J Clin Oncol. 2024. PMID: 39365960. doi:10.1200/JCO.23.02470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。